+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Rarity of Renal Osteodystrophy in Israel due to Low Phosphorus Intake

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Renal osteodystrophy is very rare in undialysed chronic renal failure in Israel, and common in Western Europe and North America. In a dietary survey it was found that there was a lower dietary phosphorus intake in Israel (942 ± 23.1 mg/ day) compared to a mean of 1,238 ± 65.0 mg/day in the UK in healthy subjects on their normal diet, whereas the daily intake of calcium was higher in Israel (1,071 ± 58.5 mg/day) compared to 887 ± 33.5 mg/day in the UK. In an investigation of non-dialysed chronic renal failure patients in Israel it was found that at all levels of renal failure in Israel plasma phosphate levels were lower than in a personal series from England and that plasma calcium levels were more frequently lower than in the UK or USA series. The plasma Ca × P product was below 70 in all cases in Israel. The data were interpreted as indicating that a lower P load in Israel resulting from a lower protein intake results in a lower plasma phosphate level at all levels of renal failure and so the development of hyperparathyroidism is delayed until a very late stage of renal failure. The results are compatible with the Bricker ‘trade-off’ hypothesis suggesting that a reduction of phosphorus intake daily in renal disease may prevent the development of renal osteodystrophy.

          Related collections

          Author and article information

          S. Karger AG
          27 November 2008
          : 10
          : 2-3
          : 141-156
          Departments of Nephrology and Dietetics, Central Negev Hospital, Beer Sheva; Department of Dietetics, Royal Infirmary, Manchester, and Negev Arid Zone Research Institute, Beer Sheva
          180183 Nephron 1973;10:141–156
          © 1973 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 16


          Comment on this article